Quantcast
Home > Quotes > AVEO
AVEO

AVEO Pharmaceuticals, Inc. Common Stock (AVEO) Quote & Summary Data

$2.0501
*  
0.0501
2.51%
Get AVEO Alerts
*Delayed - data as of Nov. 21, 2018 11:33 ET  -  Find a broker to begin trading AVEO now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    AVEO Real Time
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
$ 2.05 / $ 2.06
1 Year Target
5
Today's High / Low
$ 2.0773 / $ 2.01
Share Volume
428,094
50 Day Avg. Daily Volume
3,210,706
Previous Close
$ 2
52 Week High / Low
$ 3.59 / $ 1.49
Market Cap
256,973,061
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
1.56

Intraday Chart

Shares Traded

Share Volume:
428,094
50 Day Avg. Daily Volume:
3,210,706

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -0.40

Trading Range

The current last sale of $2.0501 is 37.59% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 2.0773 $ 3.59
 Low: $ 2.01 $ 1.49

Company Description (as filed with the SEC)

We are a biopharmaceutical company dedicated to advancing a broad portfolio of targeted medicines for oncology and other areas of unmet medical need. Our strategy is to retain North American rights to our oncology portfolio while securing partners in development and commercialization outside of North America. We are working to develop and commercialize our lead candidate tivozanib in North America as a treatment for renal cell carcinoma, or RCC. We have entered into partnerships to fund the development and commercialization of our preclinical and clinical stage assets, including AV-203 and ficlatuzumab in oncology and AV-380 in cachexia.  ... More ...  


Risk Grade

Where does AVEO fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 2.04
Open Date:
Nov. 21, 2018
Close Price:
N/A
Close Date:
N/A

Consensus Recommendation

Analyst Info



Another Bailout?? Why is the SEC boosting big banks and HFT's bottom lines?
x